Literature DB >> 9516451

Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells.

H Pollard1, J S Remy, G Loussouarn, S Demolombe, J P Behr, D Escande.   

Abstract

The beta-galactosidase reporter gene, either free or complexed with various cationic vectors, was microinjected into mammalian cells. Cationic lipids but not polyethylenimine or polylysine prevent transgene expression when complexes are injected in the nucleus. Polyethylenimine and to a lesser extent polylysine, but not cationic lipids, enhance transgene expression when complexes are injected into the cytoplasm. This latter effect was independent of the polymer vector/cDNA ionic charge ratio, suggesting that nucleic acid compaction rather than surface charge was critical for efficient nuclear trafficking. Cell division was not required for nuclear entry. Finally, comparative transfection and microinjection experiments with various cell lines confirm that barriers to gene transfer vary with cell type. We conclude that polymers but not cationic lipids promote gene delivery from the cytoplasm to the nucleus and that transgene expression in the nucleus is prevented by complexation with cationic lipids but not with cationic polymers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9516451     DOI: 10.1074/jbc.273.13.7507

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  83 in total

1.  Sequence requirements for plasmid nuclear import.

Authors:  D A Dean; B S Dean; S Muller; L C Smith
Journal:  Exp Cell Res       Date:  1999-12-15       Impact factor: 3.905

2.  Quantitative analysis of correlation between number of nuclear plasmids and gene expression activity after transfection with cationic liposomes.

Authors:  Rieko Tachibana; Hideyoshi Harashima; Naoko Ide; Sachiko Ukitsu; Yasuko Ohta; Norio Suzuki; Hiroshi Kikuchi; Yasuo Shinohara; Hiroshi Kiwada
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

3.  Diblock copolymers with tunable pH transitions for gene delivery.

Authors:  Matthew J Manganiello; Connie Cheng; Anthony J Convertine; James D Bryers; Patrick S Stayton
Journal:  Biomaterials       Date:  2011-12-12       Impact factor: 12.479

4.  Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery.

Authors:  W T Godbey; K K Wu; A G Mikos
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

5.  A novel transfecting peptide comprising a tetrameric nuclear localization sequence.

Authors:  Wolfgang Ritter; Christian Plank; James Lausier; Carsten Rudolph; Daniela Zink; Dietrich Reinhardt; Joseph Rosenecker
Journal:  J Mol Med (Berl)       Date:  2003-10-22       Impact factor: 4.599

6.  Efficient generation of mucosal and systemic antigen-specific CD8+ T-cell responses following pulmonary DNA immunization.

Authors:  Maytal Bivas-Benita; Liat Bar; Geoffrey O Gillard; David R Kaufman; Nathaniel L Simmons; Avi-Hai Hovav; Norman L Letvin
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

Review 7.  Intracellular trafficking of nucleic acids.

Authors:  Rui Zhou; R Christopher Geiger; David A Dean
Journal:  Expert Opin Drug Deliv       Date:  2004-11       Impact factor: 6.648

8.  Novel pentablock copolymers for selective gene delivery to cancer cells.

Authors:  Bingqi Zhang; Mathumai Kanapathipillai; Paul Bisso; Surya Mallapragada
Journal:  Pharm Res       Date:  2009-01-14       Impact factor: 4.200

9.  Incorporation of eukaryotic translation initiation factor eIF4E into viral nucleocapsids via interaction with hepatitis B virus polymerase.

Authors:  Seahee Kim; Haifeng Wang; Wang-Shick Ryu
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

10.  Polyplex exposure inhibits cell cycle, increases inflammatory response, and can cause protein expression without cell division.

Authors:  Rebecca L Matz; Blake Erickson; Sriram Vaidyanathan; Jolanta F Kukowska-Latallo; James R Baker; Bradford G Orr; Mark M Banaszak Holl
Journal:  Mol Pharm       Date:  2013-03-21       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.